EphB4

EphB4 Overview

English NameEphrin type-B receptor 4Approved Drugs0
Drugs in Clinical Trials2Target SynonymEphrin type-B receptor 4,MYK1,EPHB4,HTK,EPH Receptor B4,Tyrosine-Protein Kinase TYRO11,TYRO11,Tyrosine-Protein Kinase Receptor HTK,Soluble EPHB4 Variant 2,Soluble EPHB4 Variant 3,Ephrin Receptor EphB4,EC 2.7.10.1,HFASD,LMPHM7,CMAVM2,EC 2.7.10,EC:2.7.10.1,Soluble EPHB4 Variant 1,Receptor, EphB4,Hepatoma transmembrane kinase
Highest Development StagePhase 3 Clinical
English NameEphrin type-B receptor 4
Target SynonymEphrin type-B receptor 4,MYK1,EPHB4,HTK,EPH Receptor B4,Tyrosine-Protein Kinase TYRO11,TYRO11,Tyrosine-Protein Kinase Receptor HTK,Soluble EPHB4 Variant 2,Soluble EPHB4 Variant 3,Ephrin Receptor EphB4,EC 2.7.10.1,HFASD,LMPHM7,CMAVM2,EC 2.7.10,EC:2.7.10.1,Soluble EPHB4 Variant 1,Receptor, EphB4,Hepatoma transmembrane kinase
Approved Drugs0
Drugs in Clinical Trials2
Highest Development StagePhase 3 Clinical

EphB4 Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Human (2)

  • Tag

    His Tag (2)

  • Conjugate

    Unconjugated (1)Biotin-labeled (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
EP4-H5229
Human
HEK293
Human EphB4 Protein, His Tag
EP4-H8229
Human
HEK293
Biotinylated Human EphB4 Protein, His Tag, ultra sensitivity (primary amine labeling)
Total: 2
  • 1

EphB4 Background

Ephrin type-B receptor 4(EPHB4) is also known as HTK, MYK1 and TYRO11,is a member of Eph family. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. The protein encoded by EPHB4 binds to Ephrin-B2 and plays an essential role in vascular development. EPHB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EPHB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis and tumor growth. Incontrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EPHB4 is associated with prostate cancer and highly malignant breast cancers, accordingly, EPHB4 has potential application as a therapeutic candidate.

EphB4 Synonyms

EphB4,HTK,MYK1,TYRO11

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
sEphB4-HSAVas-01; sEphB4-HSAPhase 3 ClinicalVasgeneBile Duct Neoplasms; Bone metastases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Gallbladder Neoplasms; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic-Myeloproliferative Diseases; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms
Details
TesevatinibXL-647; KD-020; KD-019; EXEL-7647Phase 2 ClinicalExelixis IncBrain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Neoplasm Metastasis; Neoplasms; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive
Details
  • Overview
  • Product List
  • Clinical Drug Information